Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol-Myers Squibb Snags Another Approval for This Mega-Blockbuster Drug
03:07pm, Saturday, 07'th May 2022 The Motley Fool
The EC has approved its cancer drug Opdivo, together with chemotherapy, to treat esophageal cancer.
Bristol-Myers Squibb Snags Another Approval for This Mega-Blockbuster Drug
11:07am, Saturday, 07'th May 2022
The EC has approved its cancer drug Opdivo, together with chemotherapy, to treat esophageal cancer.
Drug companies are making an accounting change after the SEC cracked down on Biogen
05:07pm, Friday, 06'th May 2022 MarketWatch
Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in w
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
04:24pm, Friday, 06'th May 2022 Zacks Investment Research
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
02:45pm, Friday, 06'th May 2022 Zacks Investment Research
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
3 Top Biotech Stocks to Buy Right Now
02:45pm, Friday, 06'th May 2022 The Motley Fool
These three pharma stocks each pay market-beating dividends to shareholders.
Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track
02:07pm, Friday, 06'th May 2022 Zacks Investment Research
Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.
Teva's Q1 Results: Is the Stock About to Crash?
08:35pm, Thursday, 05'th May 2022 The Motley Fool
The company met analyst expectations for revenue and profitability, yet that's not necessarily a good thing.
Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat
06:14pm, Thursday, 05'th May 2022 Zacks Investment Research
Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.
5 Health Care Stocks For Your May 2022 Watchlist
03:30pm, Thursday, 05'th May 2022
Should investors' be looking at these health care stocks this earnings season?
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
06:21pm, Wednesday, 04'th May 2022 Zacks Investment Research
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News
05:39pm, Wednesday, 04'th May 2022 Zacks Investment Research
Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
03:07pm, Wednesday, 04'th May 2022 Zacks Investment Research
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
12:47pm, Wednesday, 04'th May 2022
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Called to Account: Drug companies are making an accounting change after the SEC cracked down on Biogen
03:04pm, Tuesday, 03'rd May 2022
Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in w
